A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma-Reference-Cited by-同舟云学术

A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma

Published:2022-11 Issue:6 Volume:52 Page:816-823
ISSN:0001-2998
Container-title:Seminars in Nuclear Medicine
language:en
Short-container-title:Seminars in Nuclear Medicine

Author:

Sandach Patrick,Seifert Robert^ORCID,Fendler Wolfgang P.,Hautzel Hubertus^ORCID,Herrmann Ken^ORCID,Maier Sandra,Plönes Till,Metzenmacher Martin^ORCID,Ferdinandus Justin

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging

Reference64 articles.

1. Malignant pleural mesothelioma: an epidemiological perspective;Robinson;Ann Cardiothorac Surg,2012

2. Treatment of malignant mesothelioma;Jaklitsch;World J Surg,2001

3. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province;Wagner;Br J Ind Med,1960

4. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure;Hodgson;Ann Occup Hyg,2000

5. Malignant mesothelioma: global incidence and relationship with asbestos;Bianchi;Ind Health,2007

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-12

2. Diagnostic Accuracy of Ultrasound Guided Percutaneous Pleural Needle Biopsy for Malignant Pleural Mesothelioma;Journal of Clinical Medicine;2024-04-29

3. Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease;Cancers;2023-12-06

4. Comparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma;Nuclear Medicine Communications;2023-04-28

5. Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma;Medicina;2022-12-19